{"DataElement":{"publicId":"6570073","version":"1","preferredName":"Bladder Squamous Cell Carcinoma and Adenocarcinoma AJCC Edition 8 Group Stage","preferredDefinition":"Stage group based on the combination of T, N, and M categories and relevant prognostic factors for bladder squamous cell carcinoma and adenosarcoma, using AJCC Ed. 8 criteria.","longName":"BSCAC_AJC8_DZ_STG","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6568904","version":"1","preferredName":"Bladder Neoplasm Squamous Cell Carcinoma And Adenocarcinoma Stage Grouping","preferredDefinition":"The distensible sac-like organ that functions as a reservoir of urine, collecting from the kidneys and eliminating via the urethra._A benign or malignant tissue growth resulting from uncontrolled cell proliferation._A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","longName":"2206698v1.0:6568902v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2206698","version":"1","preferredName":"Bladder Neoplasm","preferredDefinition":"A distensible musculomembranous organ serving as a receptacle for fluid, as the gallbladder.:(NEE-o-PLAY-zha) Abnormal and uncontrolled cell growth.","longName":"C12414:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bladder","conceptCode":"C12414","definition":"The distensible sac-like organ that functions as a reservoir of urine, collecting from the kidneys and eliminating via the urethra.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-008F-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6568902","version":"1","preferredName":"Squamous Cell Carcinoma And Adenocarcinoma Stage Grouping","preferredDefinition":"A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.:An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.:A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.:An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","longName":"C2929:C37912:C2852:C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Squamous Cell Carcinoma","conceptCode":"C2929","definition":"A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BA6A88C-034A-1DE6-E053-F662850AA364","latestVersionIndicator":"Yes","beginDate":"2018-11-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-27","modifiedBy":"ONEDATA","dateModified":"2018-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"7BA6A88C-035B-1DE6-E053-F662850AA364","latestVersionIndicator":"Yes","beginDate":"2018-11-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-27","modifiedBy":"TAYLORT","dateModified":"2019-08-30","changeDescription":"8-30-19 tmt released.; 11-27-18 TMT created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6570066","version":"1","preferredName":"Bladder Carcinoma American Joint Committee on Cancer Edition 8 Group Stage","preferredDefinition":"A term that refers to the staging of bladder cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to carcinomas arising in the bladder. The typical carcinoma of the bladder is urothelial carcinoma. These carcinomas may include other histologic elements, including adenocarcinoma, squamous cell carcinoma, and small cell neuroendocrine carcinoma, but should be classified as urothelial unless the cancer is composed entirely of the alternative histology. All histologic cell types that are derived primarily from the urinary bladder epithelium should follow this staging system. It does not apply to prostatic urothelial carcinomas (are staged according to the classification for urethra), lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), and sarcomas (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs).  (from AJCC 8th Ed.)_An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"6570066v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"IVB","valueDescription":"Stage IVB Bladder Cancer AJCC v8","ValueMeaning":{"publicId":"6033015","version":"1","preferredName":"Stage IVB Bladder Cancer AJCC v8","longName":"6033015","preferredDefinition":"Stage IVB includes: Any T, Any N, M1b. M1b: Non-lymph node distant metastases. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVB Bladder Cancer AJCC v8","conceptCode":"C140426","definition":"Stage IVB includes: Any T, Any N, M1b. M1b: Non-lymph node distant metastases. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F10116B-CF93-4178-E053-F662850AE49E","latestVersionIndicator":"Yes","beginDate":"2017-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BBAFB87-C0D6-556C-E053-F662850A4456","beginDate":"2018-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-28","modifiedBy":"ONEDATA","dateModified":"2018-11-28","deletedIndicator":"No"},{"value":"IVA","valueDescription":"Stage IVA Bladder Cancer AJCC v8","ValueMeaning":{"publicId":"6033017","version":"1","preferredName":"Stage IVA Bladder Cancer AJCC v8","longName":"6033017","preferredDefinition":"Stage IVA includes: (T4b, N0, M0); (Any T, Any N, M1a). T4b: Extravesical tumor invades pelvic wall, abdominal wall. N0: No regional lymph node metastasis. M0: No distant metastasis. M1a: Distant metastasis limited to lymph nodes beyond the common iliacs. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVA Bladder Cancer AJCC v8","conceptCode":"C140425","definition":"Stage IVA includes: (T4b, N0, M0); (Any T, Any N, M1a). T4b: Extravesical tumor invades pelvic wall, abdominal wall. N0: No regional lymph node metastasis. M0: No distant metastasis. M1a: Distant metastasis limited to lymph nodes beyond the common iliacs. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F10116B-CFB9-4178-E053-F662850AE49E","latestVersionIndicator":"Yes","beginDate":"2017-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BBAFB87-C0EA-556C-E053-F662850A4456","beginDate":"2018-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-28","modifiedBy":"ONEDATA","dateModified":"2018-11-28","deletedIndicator":"No"},{"value":"IIIB","valueDescription":"Stage IIIB Bladder Cancer AJCC v8","ValueMeaning":{"publicId":"6033024","version":"1","preferredName":"Stage IIIB Bladder Cancer AJCC v8","longName":"6033024","preferredDefinition":"Stage IIIB includes: T1-T4a, N2, N3, M0. T1: Tumor invades lamina propria (subepithelial connective tissue). T2: Tumor invades muscularis propria. T3: Tumor invades perivesical soft tissue. T4a: Extravesical tumor invades directly into prostatic stroma, uterus, vagina. N2: Multiple regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node metastasis). N3: Lymph node metastasis to the common iliac lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIB Bladder Cancer AJCC v8","conceptCode":"C140423","definition":"Stage IIIB includes: T1-T4a, N2, N3, M0. T1: Tumor invades lamina propria (subepithelial connective tissue). T2: Tumor invades muscularis propria. T3: Tumor invades perivesical soft tissue. T4a: Extravesical tumor invades directly into prostatic stroma, uterus, vagina. N2: Multiple regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node metastasis). N3: Lymph node metastasis to the common iliac lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F10116B-D005-4178-E053-F662850AE49E","latestVersionIndicator":"Yes","beginDate":"2017-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BBAFB87-C0FE-556C-E053-F662850A4456","beginDate":"2018-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-28","modifiedBy":"ONEDATA","dateModified":"2018-11-28","deletedIndicator":"No"},{"value":"IIIA","valueDescription":"Stage IIIA Bladder Cancer AJCC v8","ValueMeaning":{"publicId":"6033026","version":"1","preferredName":"Stage IIIA Bladder Cancer AJCC v8","longName":"6033026","preferredDefinition":"Stage IIIA includes: (T3a, T3b, T4a, N0, M0); (T1-T4a, N1, M0). T1: Tumor invades lamina propria (subepithelial connective tissue). T2: Tumor invades muscularis propria. T3: Tumor invades perivesical soft tissue. T3a: Tumor invades perivesical soft tissue, microscopically. T3b: Tumor invades perivesical soft tissue, macroscopically (extravesical mass). T4a: Extravesical tumor invades directly into prostatic stroma, uterus, vagina. N0: No regional lymph node metastasis. N1: Single regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node). M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIA Bladder Cancer AJCC v8","conceptCode":"C140422","definition":"Stage IIIA includes: (T3a, T3b, T4a, N0, M0); (T1-T4a, N1, M0). T1: Tumor invades lamina propria (subepithelial connective tissue). T2: Tumor invades muscularis propria. T3: Tumor invades perivesical soft tissue. T3a: Tumor invades perivesical soft tissue, microscopically. T3b: Tumor invades perivesical soft tissue, macroscopically (extravesical mass). T4a: Extravesical tumor invades directly into prostatic stroma, uterus, vagina. N0: No regional lymph node metastasis. N1: Single regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node). M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F10116B-D02B-4178-E053-F662850AE49E","latestVersionIndicator":"Yes","beginDate":"2017-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BBAFB87-C112-556C-E053-F662850A4456","beginDate":"2018-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-28","modifiedBy":"ONEDATA","dateModified":"2018-11-28","deletedIndicator":"No"},{"value":"II","valueDescription":"Stage II Bladder Cancer AJCC v8","ValueMeaning":{"publicId":"6033030","version":"1","preferredName":"Stage II Bladder Cancer AJCC v8","longName":"6033030","preferredDefinition":"Stage II includes: (T2a, N0, M0); (T2b, N0, M0). T2a: Tumor invades superficial muscularis propria (inner half). T2b: Tumor invades deep muscularis propria (outer half). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage II Bladder Cancer AJCC v8","conceptCode":"C140420","definition":"Stage II includes: (T2a, N0, M0); (T2b, N0, M0). T2a: Tumor invades superficial muscularis propria (inner half). T2b: Tumor invades deep muscularis propria (outer half). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F10116B-D077-4178-E053-F662850AE49E","latestVersionIndicator":"Yes","beginDate":"2017-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BBAFB87-C126-556C-E053-F662850A4456","beginDate":"2018-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-28","modifiedBy":"ONEDATA","dateModified":"2018-11-28","deletedIndicator":"No"},{"value":"I","valueDescription":"Stage I Bladder Cancer AJCC v8","ValueMeaning":{"publicId":"6033032","version":"1","preferredName":"Stage I Bladder Cancer AJCC v8","longName":"6033032","preferredDefinition":"Stage I includes: T1, N0, M0. T1: Tumor invades lamina propria (subepithelial connective tissue). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I Bladder Cancer AJCC v8","conceptCode":"C140419","definition":"Stage I includes: T1, N0, M0. T1: Tumor invades lamina propria (subepithelial connective tissue). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F10116B-D09D-4178-E053-F662850AE49E","latestVersionIndicator":"Yes","beginDate":"2017-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BBAFB87-C13A-556C-E053-F662850A4456","beginDate":"2018-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-28","modifiedBy":"ONEDATA","dateModified":"2018-11-28","deletedIndicator":"No"},{"value":"0is","valueDescription":"Stage 0is Bladder Cancer AJCC v8","ValueMeaning":{"publicId":"6033034","version":"1","preferredName":"Stage 0is Bladder Cancer AJCC v8","longName":"6033034","preferredDefinition":"Stage 0is includes: Tis, N0, M0. Tis: Urothelial carcinoma in situ: \"flat tumor\". N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0is Bladder Cancer AJCC v8","conceptCode":"C140418","definition":"Stage 0is includes: Tis, N0, M0. Tis: Urothelial carcinoma in situ: \"flat tumor\". N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F10116B-D0C3-4178-E053-F662850AE49E","latestVersionIndicator":"Yes","beginDate":"2017-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BBAFB87-C144-556C-E053-F662850A4456","beginDate":"2018-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-28","modifiedBy":"ONEDATA","dateModified":"2018-11-28","deletedIndicator":"No"},{"value":"0a","valueDescription":"Stage 0a Bladder Cancer AJCC v8","ValueMeaning":{"publicId":"6033036","version":"1","preferredName":"Stage 0a Bladder Cancer AJCC v8","longName":"6033036","preferredDefinition":"Stage 0a includes: Ta, N0, M0. Ta: Non-invasive papillary carcinoma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0a Bladder Cancer AJCC v8","conceptCode":"C140417","definition":"Stage 0a includes: Ta, N0, M0. Ta: Non-invasive papillary carcinoma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F10116B-D0E9-4178-E053-F662850AE49E","latestVersionIndicator":"Yes","beginDate":"2017-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BBAFB87-C14E-556C-E053-F662850A4456","beginDate":"2018-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-28","modifiedBy":"ONEDATA","dateModified":"2018-11-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6570065","version":"1","preferredName":"Bladder Cancer by AJCC v8 Stage Stage Grouping Stage","preferredDefinition":"A term that refers to the staging of bladder cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to carcinomas arising in the bladder. The typical carcinoma of the bladder is urothelial carcinoma. These carcinomas may include other histologic elements, including adenocarcinoma, squamous cell carcinoma, and small cell neuroendocrine carcinoma, but should be classified as urothelial unless the cancer is composed entirely of the alternative histology. All histologic cell types that are derived primarily from the urinary bladder epithelium should follow this staging system. It does not apply to prostatic urothelial carcinomas (are staged according to the classification for urethra), lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), and sarcomas (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs).  (from AJCC 8th Ed.):An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C140416:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bladder Cancer by AJCC v8 Stage","conceptCode":"C140416","definition":"A term that refers to the staging of bladder cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to carcinomas arising in the bladder. The typical carcinoma of the bladder is urothelial carcinoma. These carcinomas may include other histologic elements, including adenocarcinoma, squamous cell carcinoma, and small cell neuroendocrine carcinoma, but should be classified as urothelial unless the cancer is composed entirely of the alternative histology. All histologic cell types that are derived primarily from the urinary bladder epithelium should follow this staging system. It does not apply to prostatic urothelial carcinomas (are staged according to the classification for urethra), lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), and sarcomas (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs).  (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BBAFB87-C0A2-556C-E053-F662850A4456","latestVersionIndicator":"Yes","beginDate":"2018-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-28","modifiedBy":"ONEDATA","dateModified":"2018-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7BBAFB87-C0B3-556C-E053-F662850A4456","latestVersionIndicator":"Yes","beginDate":"2018-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-28","modifiedBy":"TAYLORT","dateModified":"2019-08-30","changeDescription":"8-20-19 released per MC.; 11/29/2018 TMT created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"10000515","version":"1","longName":"Bladder","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Disease stage","type":"Preferred Question Text","description":"Disease stage","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7BBC51FE-DC3B-5579-E053-F662850A0913","latestVersionIndicator":"Yes","beginDate":"2018-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-28","modifiedBy":"TAYLORT","dateModified":"2019-08-30","changeDescription":"8-30-19 TMT released per MC.; 11/28/2018 TMT created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}